Lisata Therapeutics (LSTA) SVP receives restricted stock and options

Rhea-AI Filing Summary

Lisata Therapeutics, Inc. reported equity awards and related tax withholdings for senior executive James Nisco, SVP Finance, Treasurer and Chief Accounting Officer. On January 9, 2026, he received 15,000 shares of restricted common stock at a price of $0 under the company’s 2018 Equity Incentive Compensation Plan. These restricted shares vest in four equal parts, with one quarter vesting on the grant date and additional quarters vesting on each of the first, second and third anniversaries of the grant.

The filing also shows tax-related share withholdings: blocks of 2,131, 2,131, 1,137 and 781 common shares were withheld at $1.97 per share to cover taxes upon vesting of restricted stock. After these transactions, Nisco directly held 32,311 shares of common stock, which include 20,750 unvested restricted shares.

In addition, Nisco was granted a stock option for 7,000 shares of common stock at an exercise price of $1.97 per share. One quarter of the option vested on the grant date, with further quarters scheduled to vest on the first, second and third anniversaries of January 9, 2026, and the option expires on January 9, 2036.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nisco James

(Last) (First) (Middle)

C/O LISATA THERAPEUTICS, INC.

110 ALLEN ROAD, 2ND FLOOR

(Street)

BASKING RIDGE NJ 07920

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LISATA THERAPEUTICS, INC. [ LSTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Fin/Treas, Chief Actg Off

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/09/2026		A		15,000(1)	A	$0	38,491(2)	D
Common Stock	01/09/2026		F		2,131(3)	D	$1.97	36,360(2)	D
Common Stock	01/09/2026		F		2,131(3)	D	$1.97	34,229(2)	D
Common Stock	01/09/2026		F		1,137(3)	D	$1.97	33,092(2)	D
Common Stock	01/09/2026		F		781(3)	D	$1.97	32,311(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.97	01/09/2026		A		7,000		01/09/2026(4)	01/09/2036	Common Stock	7,000	$0	7,000	D

Explanation of Responses:

1. Represents 15,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.

2. Includes 20,750 unvested restricted stock.

3. Shares withheld as payment of a tax liability on vesting of restricted stock.

4. One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date.

Remarks:

	James Nisco	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Lisata Therapeutics (LSTA) report for James Nisco?

The report shows that James Nisco, SVP Finance, Treasurer and Chief Accounting Officer of Lisata Therapeutics, Inc., received 15,000 restricted shares of common stock and a stock option for 7,000 shares on January 9, 2026, along with several tax-related share withholdings.

How many restricted Lisata Therapeutics (LSTA) shares were granted to James Nisco?

Nisco was granted 15,000 restricted shares of common stock under Lisata’s 2018 Equity Incentive Compensation Plan. These awards were recorded at a price of $0 per share, reflecting that they were granted as equity compensation rather than purchased in the market.

What is the vesting schedule for James Nisco’s restricted stock and stock options at Lisata Therapeutics (LSTA)?

The 15,000 restricted shares vest in four equal installments: one quarter on the grant date and one quarter on each of the first, second and third anniversaries of January 9, 2026. The 7,000-share stock option at an exercise price of $1.97 per share also vests in four equal annual installments on the grant date and the first three anniversaries, and it expires on January 9, 2036.

Why were Lisata Therapeutics (LSTA) shares withheld in James Nisco’s Form 4 filing?

The filing notes that several blocks of common stock—2,131, 2,131, 1,137 and 781 shares—were withheld at $1.97 per share as payment of a tax liability on the vesting of restricted stock. This is a common method for covering taxes due when restricted shares vest.

How many Lisata Therapeutics (LSTA) shares does James Nisco own after these transactions?

After the reported grants and tax-related withholdings, James Nisco directly owned 32,311 shares of Lisata Therapeutics common stock. This amount includes 20,750 unvested restricted shares as described in the explanatory footnotes.

What are the key terms of James Nisco’s Lisata Therapeutics (LSTA) stock option grant?

The stock option covers 7,000 shares of common stock with an exercise price of $1.97 per share. One quarter of the option vested on January 9, 2026, with additional quarters vesting on the first, second and third anniversaries of that date. The option is scheduled to expire on January 9, 2036 if not exercised earlier.